|--|

Check this box if no	Ī
longer subject to	
Section 16. Form 4 or	
Form 5 obligations	1
may continue. See	1
Instruction 1(b).	

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

gations i.e. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment (b) Company Act of 1940

1. Name and Address of Reporting Pe Nolan Lisa	2. Issuer Name and REXAHN PHAR			0 2		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director					
(Last) (First) C/O REXAHN PHARMACEUT INC., 15245 SHADY GROVE I	TICALS,	3. Date of Earliest Transaction (Month/Day/Year) 01/20/2017						X Officer (give title below) Other (specify below) Chief Business Officer			
(Street) ROCKVILLE, MD 20850		4. If Amendment, Da	ate Original	Filed	(Month/Day	/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)	Т	able I - No	n-De	rivative S	Securities	s Acqu	ired, Disposed of, or Beneficially Own	ned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if	Code (Instr. 8)		(A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Ownership of	Beneficial	
		(Code	v	Amount	(A) or (D)	Price	x ,	or Indirect (I) (Instr. 4)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
	Conversion	Date (Month/Day/Year)		Code	ansaction Derivative ode Securities			(Month/Day/Year)				Derivative Security (Instr. 5)	Securities Beneficially Owned Following	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (right to buy)	\$ 0.184	01/20/2017		А		315,000		Ш	01/20/2027	Common Stock	315,000	\$ 0	315,000	D	
Restricted Stock Units	<u>(2)</u>	01/20/2017		А		65,000		<u>(3)</u>	<u>(3)</u>	Common Stock	65,000	\$ 0	65,000	D	

Reporting Owners

Reporting Owner Name / Address	Relationships							
Reporting Owner Pounce/ Producess	Director	10% Owner	Officer	Other				
Nolan Lisa C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850			Chief Business Officer					

Signatures

/s/ Tae Heum Jeong, as attorney-in-fact for Lisa Nolan

01/24/2017
Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) One quarter of the option vests and becomes exercisable on January 20, 2018, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested.
- (2) Each restricted stock unit represents a contingent right to receive one share of common stock.
- (3) The restricted stock units vest in four equal annual installments on the last business day in February, beginning February 28, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.